Company / Net Income
Charles River Laboratories Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$144.3M
FY2025
5-year range
-$144.3M / $391.0M
FY2021-FY2025
Trend
-750.1%
vs FY2024
Sector context
#137 of 163
Health Care
What the data says
Net Income changed -750% YoY in FY2025, a notable deviation from the 9-year average annual change of -76%.
Based on SEC 10-K filings.
-$144M in FY2025.
Declined from $391M to -$144M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 163This company -$144.3M Sector average $467.8M
▼
-130.9% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 750.1% year-over-year.
- Ranks #137 out of 163 companies in the Health Care sector.
- Peak net income was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$144.3M | -750.1% |
| FY2024 | $22.2M | -94.3% |
| FY2023 | $391.0M | +7.3% |
| FY2022 | $364.3M | +44.6% |
| FY2021 | $252.0M | +11.3% |
| FY2020 | $226.4M | +83.5% |
| FY2019 | $123.4M | -45.5% |
| FY2018 | $226.4M | +83.5% |
| FY2017 | $123.4M | -20.3% |
| FY2016 | $154.8M | +50.5% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026